Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833273 · ClinicalTrials.gov registry record · Phase 1
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
A Phase 1 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01833273 is a Phase 1 study that has completed, run by Stony Brook University. The registered enrollment target is 13 participants.
The verdict
NCT01833273, a Phase 1 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
In order to test the investigators hypothesis that 8 teaspoons of POLYMVA is safe in a population of patients with grade IV brain astrocytoma (glioblastoma multiforme), the investigators will conduct an open-label, prospective, un-blinded study. The investigators expect that at least 70% of subjects will tolerate the supplement and complete the trial. The investigators expect no Serious Adverse Event to occur during this trial which is attributable to study compound. During this study, the investigators will also collect other qualitative data to be utilized for future double-blinded studies which will be aimed at determining whether grade IV astrocytoma patients who receive PolyMVA achieve a better quality of life during their chemo-therapeutic regimens versus grade IV astrocytoma patients who do not receive PolyMVA.
Interventions
- DRUG PolyMVA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01833273
The ClinicalTrials.gov registry entry for NCT01833273 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PolyMVA is the first listed.
NCT01833273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01833273 about?
NCT01833273 is a clinical study titled "Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA". In order to test the investigators hypothesis that 8 teaspoons of POLYMVA is safe in a population of patients with grade IV brain astrocytoma (glioblastoma multiforme), the investigators will conduct an open-label, prospective, un-blinded study. The investigators expect that at least 70% of subjects...
What is the current status of trial NCT01833273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2010-07. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01833273?
The interventions under investigation include: PolyMVA (DRUG).
Who is sponsoring clinical trial NCT01833273?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.